{"id":59621,"date":"2024-07-01T13:04:51","date_gmt":"2024-07-01T11:04:51","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/"},"modified":"2024-07-01T13:04:51","modified_gmt":"2024-07-01T11:04:51","slug":"precision-biosciences-announces-its-addition-to-the-russell-microcap-index","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/","title":{"rendered":"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index"},"content":{"rendered":"
\n

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russell Microcap\u00ae Index. Precision\u2019s inclusion in the index follows the conclusion of the 2024 Russell indexes annual reconstitution, which became effective after the close of U.S. markets on June 28, 2024.<\/p>\n

<\/a>
<\/a><\/p>\n

\n“We are pleased to be added to the Index, which highlights our continued progress in advancing our wholly owned PBGENE-HBV and PBGENE-PMM in vivo<\/i> gene editing programs towards investigational new drug (IND) and\/or clinical trial applications (CTA) in 2024 and 2025, respectively,\u201d said Michael Amoroso, Chief Executive Officer at Precision BioSciences. “With this inclusion, we believe that the increased visibility amongst the global investment community will continue to drive awareness and interest as we establish Precision as a leading in vivo<\/i> gene editing company.”<\/p>\n

\nThe annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of Tuesday, April 30th<\/sup>, ranking them by total market capitalization. Membership in the Russell Microcap\u00ae <\/sup>Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.<\/p>\n

\nRussell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Russell\u2019s US indexes serve as the benchmark for about $10.5 trillion in assets as of the close of December 2023. Russell indexes are part of FTSE Russell, a leading global index provider.<\/p>\n

\nFor more information on the Russell Microcap\u00ae <\/sup>Index and the Russell indexes reconstitution, go to the \u201cRussell Reconstitution\u201d section on the FTSE Russell website<\/a>.<\/p>\n

\nAbout Precision BioSciences, Inc.<\/b><\/p>\n

\nPrecision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS\u00ae genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more intended, defined therapeutic outcomes. Using ARCUS, the Company\u2019s pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit www.precisionbiosciences.com<\/a>.<\/p>\n

\nThe ARCUS\u00ae platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression\/add function), elimination (removing a genome e.g. viral DNA or mutant mitochondrial DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV).<\/p>\n

\nAbout FTSE Russell<\/b><\/p>\n

\nFTSE Russell is a leading global provider of benchmarking, analytics, and data solutions for investors, giving them a precise view of the market relevant to their investment process. A comprehensive range of reliable and accurate indexes provides investors worldwide with the tools they require to measure and benchmark markets across asset classes, styles, or strategies.<\/p>\n

\nFTSE Russell index expertise and products are used extensively by institutional and retail investors globally. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products, and index-based derivatives. \u200b\u200b\u200b\u200b\u200b\u200b\u200b<\/p>\n

\nFTSE Russell is focused on applying the highest industry standards in index design and governance, employing transparent rules-based methodology informed by independent committees of leading market participants. FTSE Russell fully embraces the IOSCO Principles, and its Statement of Compliance has received independent assurance. Index innovation is driven by client needs and customer partnerships, allowing FTSE Russell to continually enhance the breadth, depth and reach of its offering.<\/p>\n

\nFTSE Russell is wholly owned by London Stock Exchange Group.<\/p>\n

\nFor more information, visit https:\/\/www.lseg.com\/en\/ftse-russell<\/a>.<\/p>\n

\nForward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the clinical development and expected safety, efficacy and benefit of our product candidates and gene editing approaches including editing efficiency; the suitability of ARCUS nucleases for gene elimination, insertion and excision and differentiation from other gene editing; the expected timing of regulatory processes (including filings such as IND\u2019s and CTA\u2019s and studies for PBGENE-HBV and PBGENE-PMM); expectations about operational initiatives, strategies, and further development of our programs; expectations about achievement of key milestones; and anticipated timing of clinical data. In some cases, you can identify forward-looking statements by terms such as \u201caim,\u201d \u201canticipate,\u201d \u201capproach,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201ccould,\u201d \u201cdesigned,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201cgoal,\u201d \u201cintend,\u201d \u201clook,\u201d \u201cmay,\u201d \u201cmission,\u201d \u201cplan,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpursue,\u201d \u201cshould,\u201d \u201cstrive,\u201d \u201ctarget,\u201d \u201cwill,\u201d \u201cwould,\u201d or the negative thereof and similar words and expressions.<\/p>\n

\nForward-looking statements are based on management\u2019s current expectations, beliefs and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and\/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators\u2019 or other licensees\u2019 ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the US and foreign regulatory landscape applicable to our and our collaborators\u2019 or other licensees\u2019 development of product candidates; our or our collaborators\u2019 or other licensees\u2019 ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators\u2019 and other licensees\u2019 ability to enroll patients; changes in interim \u201ctop-line\u201d and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees\u2019 ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators\u2019 or other licensees\u2019 ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and\/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption \u201cRisk Factors\u201d in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC\u2019s website at www.sec.gov<\/a> and the Investors page of our website under SEC Filings at investor.precisionbiosciences.com<\/a>.<\/p>\n

\nAll forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor and Media Contact:<\/b>
Naresh Tanna
\n
Vice President of Investor Relations
\n
naresh.tanna@precisionbiosciences.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russell Microcap\u00ae Index. Precision\u2019s inclusion in the index follows the conclusion of the 2024 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-59621","6":"format-standard","7":"category-industry"},"yoast_head":"\nPrecision BioSciences Announces its Addition to the Russell Microcap\u00ae Index - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russell Microcap\u00ae Index. Precision\u2019s inclusion in the index follows the conclusion of the 2024 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-01T11:04:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20240701363296\/en\/593587\/22\/Precision_BioSciences_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index\",\"datePublished\":\"2024-07-01T11:04:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/\"},\"wordCount\":1593,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240701363296\\\/en\\\/593587\\\/22\\\/Precision_BioSciences_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/\",\"name\":\"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240701363296\\\/en\\\/593587\\\/22\\\/Precision_BioSciences_logo.jpg\",\"datePublished\":\"2024-07-01T11:04:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240701363296\\\/en\\\/593587\\\/22\\\/Precision_BioSciences_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20240701363296\\\/en\\\/593587\\\/22\\\/Precision_BioSciences_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/","og_locale":"en_US","og_type":"article","og_title":"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index - Pharma Trend","og_description":"DURHAM, N.C.–(BUSINESS WIRE)–Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS\u00ae platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced its addition to the Russell Microcap\u00ae Index. Precision\u2019s inclusion in the index follows the conclusion of the 2024 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/","og_site_name":"Pharma Trend","article_published_time":"2024-07-01T11:04:51+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20240701363296\/en\/593587\/22\/Precision_BioSciences_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index","datePublished":"2024-07-01T11:04:51+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/"},"wordCount":1593,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240701363296\/en\/593587\/22\/Precision_BioSciences_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/","url":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/","name":"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20240701363296\/en\/593587\/22\/Precision_BioSciences_logo.jpg","datePublished":"2024-07-01T11:04:51+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20240701363296\/en\/593587\/22\/Precision_BioSciences_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20240701363296\/en\/593587\/22\/Precision_BioSciences_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/precision-biosciences-announces-its-addition-to-the-russell-microcap-index\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Precision BioSciences Announces its Addition to the Russell Microcap\u00ae Index"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59621","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=59621"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/59621\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=59621"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=59621"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=59621"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}